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Abstract
Duffy Antigen Receptor for Chemokines (DARC) plays multiple roles in human health as a
blood group antigen, a receptor for chemokines and the only known receptor for Plasmodi-
um vivaxmerozoites. It is the target of the murine anti-Fy6 monoclonal antibody 2C3 which
binds to the first extracellular domain (ECD1), but exact nature of the recognized epitope
was a subject of contradictory reports. Here, using a set of complex experiments which in-
clude expression of DARC with amino acid substitutions within the Fy6 epitope in E. coli
and K562 cells, ELISA, surface plasmon resonance (SPR) and flow cytometry, we have re-
solved discrepancies between previously published reports and show that the basic epitope
recognized by 2C3 antibody is 22FEDVW26, with 22F and 26W being the most important resi-
dues. In addition, we demonstrated that 30Y plays an auxiliary role in binding, particularly
when the residue is sulfated. The STD-NMR studies performed using 2C3-derived Fab and
synthetic peptide corroborated most of these results, and together with the molecular
modelling suggested that 25V is not involved in direct interactions with the antibody, but de-
termines folding of the epitope backbone.
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Introduction
Duffy Antigen Receptor for Chemokines (DARC) is a seven-transmembrane domain
glycoprotein present on red blood cells (RBC) and post-capillary endothelial cells or Purkinje
cells. DARC plays an important role in human health, being a blood group antigen, the only
known receptor for Plasmodium vivax parasite that causes malaria and a receptor
for chemokines.
DARC glycoprotein carries blood group antigens Fya and Fyb, which are encoded by two al-
lelic genes, designated FY01 and FY02 respectively. The Fya/Fyb polymorphism depends on
the presence of Gly or Asp residue at position 42 in the polypeptide chain of DARC (Gly in
Fya, Asp in Fyb). The third common allele called FY02N.01 occurs mostly in Africans or Afri-
can-American people and results in the lack of DARC expression on erythrocytes, but not on
other tissues. That phenotype, called Fy(a-b-) is caused by a single nucleotide polymorphism at
position -67T>C in the GATA box of DARC gene promoter [1] and it was thought for decades
that it was associated with resistance of red blood cells to infection by Plasmodium vivaxmero-
zoites [2]. However, recent data cast some doubt on this dogma, suggesting that another recep-
tor for P. vivaxmay exist [3]. P. vivax is the most widespread species of parasite causing
malaria with about 2.85 billion of people living in endemic regions. DARC is recognized by
P. vivax Duffy Binding Protein (PvDBP), and thus serves as a receptor for P. vivaxmerozoites
[4, 5]. The crystal structure of DARC-PvDBP complex has been recently resolved [5].
DARC is also a chemokine receptor belonging to G-Protein Coupled Receptor (GPCR) fam-
ily [6, 7], and this function most probably determines DARC’s involvement in malignancies
[8–10], inflammation [11], HIV infection or AIDS progression [12–14]. DARC binds chemo-
kines [15], but lacks the DRY motif which is typical for this family of receptors and required
for signal transduction, hence it was considered a “silent chemokine receptor” [16, 17]. Recent-
ly, it was proposed to call it Atypical Chemokine Receptor 1 (ACKR1) [18]. It was shown that
DARC plays an important role in regulation of the chemokine level, but in a different manner
depending on its localization: on the erythrocytes it serves as a reservoir of chemokines, while
on the endothelial cells it facilitates chemokines translocation through the vessel walls.
DARC contains three N-linked oligosaccharide chains located at Asn-16, 27, and 33 [19].
These moieties are mostly of triantennary complex type, terminated with sialic acid residues
[19–21]. In addition, Tyr-30 and 41 are sulfated [22], and sulfation of Tyr-41 increases binding
of PvDBP to DARC approximately thousand times [22].
There are several epitopes recognized by human and murine antibodies on DARC: two of
them determine the Fya/Fyb blood group status, the other is Fy3, a conformational epitope con-
sisting of fragments of extracellular domains 1 and 3, and a linear epitope called Fy6, present
on the ECD1 of the protein.
Specificities of several monoclonal anti-Fy6 antibodies have been precisely defined [23–25].
It was found that all tested antibodies with anti-Fy6 specificity recognize linear epitopes con-
taining 19QLDFEDV25 sequence located between two potential N-glycosylation sites of Duffy
protein, Asn-16 and Asn-27. One of the widely used anti-DARC antibodies, monoclonal anti-
body 2C3 with anti-Fy6 specificity, was obtained after immunization of mice with CHO cells
transfected with the vector encoding DARC. Its epitope was evaluated by Wasniowska et al.
using Pepscan analysis, and determined to be a linear sequence 22FEDVW26, in which only
Asp-24 may be replaced by other amino acids without influencing binding of the antibody
[24]. In contrast, Tournamille et al., using recombinant forms of DARC expressed in K562
cells suggested that Trp-26 can be substituted by other amino acids without losing reactivity to
2C3 antibody. In addition, it was claimed that the antibody does not bind to the recombinant
form of Duffy antigen, in which Tyr-30 is substituted by another amino acid [25].
Anti-DARCMonoclonal Antibody
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Since antibodies that recognize Fy6 epitope can inhibit interaction between chemokines
[26] or PvDBP [27] and DARC, the exact determination of epitope recognized by 2C3 antibody
is of great importance. The aim of our study was to precisely characterize the epitope recog-
nized by 2C3 antibody and to resolve discrepancies between the two abovementioned reports.
To this end, we prepared two sets of constructs: one set comprised the full-length consensus
DARC or mutants with substitutions introduced in the first extracellular domain (ECD1);
these constructs were expressed in K562 cells. The other set comprised the consensus or mu-
tant ECD1 (with the same substitutions as in the full-length DARC mutants) fused in-frame to
nuclease from Staphylococcus aureus and expressed in E. coli. The proteins obtained in E. coli
or K562 cells were used to evaluate the binding of 2C3 antibody using ELISA, SPR and flow cy-
tometry. In addition, we employed saturation transfer difference spectroscopy (STD-NMR) of
a 2C3-derived Fab fragment with a synthetic peptide encompassing the Fy6 epitope in order to
precisely define how the side chains of amino acids interact with the Fab.
Materials and Methods
Monoclonal antibody
MAb 2C3 (clone name NaM185-2C3) was obtained previously by immunizing mice with
CHO cells transfected with the vector encoding DARC protein [24].
Recombinant proteins used as reagents for 2C3 MAb studies
Constructs with substitutions of amino acids located within or in the vicinity of the Fy6 epitope
were prepared by mutagenesis using plasmid containing first extracellular domain of DARC
followed by nuclease from Staphylococcus aureus as a template [26].
The protein (called thereafter ECD1-nuc) was expressed in E. coli BL21 strain (New En-
gland Biolabs, Ipswich, MA, USA) grown in autoinduction medium, and purified from whole
cell extract using ion exchange Capto-S column (GE Healthcare, Little Chalfont, UK) followed
by reversed-phase liquid chromatography on a Vydac TCP 104 column (Grace, Columbia,
MD, USA).
The full-length DARC was purified from K562 cells expressing DARC, essentially as de-
scribed [26] by immunochromatography on an immobilized camel antibody fragment (nano-
body), but using a column format. Briefly, 16 × 108 cells were lyzed in 300 ml of lysis buffer
(20 mM Tris-HCl pH 8.0 containing 0.15 M NaCl, 5 mM EDTA, 1% Triton X100 and
protease inhibitors (cOmplete, Roche, Basel, Switzerland). After centrifugation, supernatant
was loaded at 15 ml/hour onto a 1 ml affinity column (prepared using NHS-activated Sephar-
ose and purified anti-DARC nanobody). After washing the column with lysis buffer followed
by 20 mM Tris-HCl pH 8.0 containing 0.15 M NaCl and 0.3% C12E8 detergent (Sigma),
DARC was eluted by passing onto the colum 5 ml of peptide DFEDVW (dissolved in the
latter buffer at 4 mg/ml concentration). Column was further rinsed with 0.1 M Glycine pH 2.8.
DARC was freed of peptide by dialysis. The DARC purity was evaluated by SDS-PAGE
(S1 Fig.).
Cloning and expression of 2C3 Fab fragment
cDNA encoding variable regions of the 2C3 Fab fragment was cloned by PCR using total RNA
extracted from 2C3-producing hybridoma cells. The amplified DNA was cloned into
pComb3H vector, expressed in E. coli and purified as described previously [28, 29]. The Fab
purity was evaluated by SDS-PAGE (S2 Fig.).
Anti-DARCMonoclonal Antibody
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ELISA
Microtiter 96-well plate (MaxiSorb, Nunc, Roskilde, Denmark) was coated with wild-type
ECD1-nuc 0.1 μg of protein per well in 50 μl of carbonate buffer pH 9.6, overnight at 4°C. Non-
specific binding was blocked by incubation for 1 hour at room temperature with TBS (Tris-
buffered saline: 20 mM Tris-HCl, and 150 mMNaCl pH 7.4) containing 5% non-fat dry milk.
After washing the wells once with TBS, 50 μl of 2C3 MAb or 2C3 Fab fragments appropriately
diluted in TBS were added to each well, and the mixture was incubated for 1 h at room temper-
ature. After five washes with TBS, 50 μl of a 1000 x dilution in TBS of rabbit anti-Fab antiserum
conjugated with alkaline phosphatase or avidin-alkaline phosphatase 1000 x diluted (Pierce,
Rockford, IL, USA) were added to each well and the plates were incubated for 1 h at room tem-
perature. To develop the reaction, p-nitrophenylphosphate was used (1 mg/ml in 60 mM car-
bonate buffer, pH 9.5, containing 1 mMMgCl2); the OD405 was determined using Perkin
Elmer EnSpire 2300 Multilabel Reader (Waltham, MA, USA). All experiments were performed
in triplicates.
Inhibition of the antibody binding was evaluated by incubating appropriately diluted MAb
or Fab with serially diluted ECD1-nuc mutants for 1h. The samples were then applied on the
coated plate and incubated for 10 min, and the bound antibody was detected as described
above. The percentage of inhibition was calculated as: [1- (OD405 of sample)/(OD405 of con-
trol)] x100.
Surface plasmon resonance (SPR)
All experiments were performed in the Biacore X100 machine using CM5 type sensor chips
(GE Healthcare), the running buffer was HBS-EP (GE Healthcare). To immobilize proteins,
amine coupling procedure was used according to the manufacturer’s instructions. 2C3 MAb or
2C3 Fab was immobilized in the flow cell, and murine monoclonal anti-Kx2 antibody [30] was
immobilized in the reference cell. Approximately 400 RU of protein was immobilized in each
flow cell. ECD1-nuc with wild type or mutated sequences were used as analytes, and each con-
struct was evaluated in 5 different concentrations. 50 mMHCl was used for regeneration of the
chip. The association phase (binding of ligand) was run for 100 sec., and then dissociation was
continued for 600 sec. The results were processed using BIAevaluation software and 1:1 Lang-
muir binding model.
For SPR inhibition assay, 2000 RU ofWT ECD1-nuc construct was immobilized on Fc2
channel of a sensor chip as described above, with S. aureus nuclease in the Fc1 reference cell. 2C3
MAb (culture supernatant diluted 40 times) was incubated with the ECD1-nuc constructs at
room temperature for one hour, the samples were then applied to the chip, the association phase
was continued for 100 sec., and the RU value was read at 90 sec. The obtained values were used
to calculate the concentration of each ECD1 mutant causing 50% inhibition of binding of 2C3 to
ECD1-nuc. The synthetic peptides with sequences DFEDVWNSSYG and DFEDVWNSSY
(SO3H)G were obtained from Cambridge Research Biochemicals, Clevelend, UK.
To evaluate how the presence of a negative charge on tyrosine residues influences the anti-
gen binding, the ECD1-nuc construct was phosphorylated by Src kinase (Cell Signalling Tech-
nology, Danvers, MA, USA) and binding of 2C3 Fab to the phosphorylated ligand was studied.
Phosphorylation of proteins already immobilized on the sensor chip was performed in the Bia-
core apparatus. Constructs of ECD1-nuc were used as a ligand and nuclease was immobilized
in the reference cell (the phosphorylation site on Tyr-54 of nuclease was removed by mutagen-
esis from both ECD1-nuc and nuclease constructs). The phosphorylation reaction mixture
was prepared by mixing Src Kinase (25 ng/μl final concentration), calcium-calmodulin (Sigma,
58 ng/μl final concentration), and ATP (73 μM final concentration) in the buffer supplied by
Anti-DARCMonoclonal Antibody
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the enzyme manufacturer. The mixture was injected at 5 μl/minute in two pulses of 1060 and
470 seconds onto the chip equilibrated at 37°C.
DARC purified from DARC-expressing K562 cells by immunochromatography on immobi-
lized anti-DARC VHH (S1 Fig.) was immobilized at ca. 400 RU on the analysis flow cell, the
reference cell was only activated and deactivated.
Analysis of the influence of glycosylation on binding to DARC was performed by in situ
deglycosylation of purified DARC immobilized on the chip. Reaction mixture prepared by di-
luting N-glycosidase (New England Biolabs, Ipswich, MA, USA) to 50 UI/μl in the buffer rec-
ommended by the manufacturer was injected three times for 1000 sec. each time, the
temperature was set to 37°C and flow rate to 5 μl/min. To evaluate efficiency of the deglycosyla-
tion process, Sambucus nigra lectin (Vector Labs, Burlingname, CA, USA) in concentration
70 nM and 7 nM was injected.
Transfection of K562 cells
The mutants were prepared using the Quickchange kit according to the manufacturer’s in-
struction (Stratagene, La Jolla, CA, USA). 2 × 106 of K562 cells (obtained from ATCC, Manas-
sas, VA, USA, clone number CCL-243) were transfected with vector encoding DARC using
Amaxa Nucleofector system (Lonza, Basel, Switzerland). The DARC-expressing cells were se-
lected for resistance to geneticin, as described [19].
Flow Cytometry analysis
Approximately 106 of K562 cells transfected with vector encoding DARC were used in each
analysis. After washing with PBS, the cells were incubated for 1 hour with either one of three
antibody solutions in PBS-0.2% BSA: i) anti-mouse IgG (Sigma, St. Louis, MO, USA) as a nega-
tive control, ii) anti-Fya human antibody (clone 665, kindly provided by Dr. F. Buffiere, Bor-
deaux, France) as a positive control [25], iii) 2C3 MAb culture supernatant. The cells were then
washed 3 times with PBS, and incubated in the dark with secondary antibody conjugated to PE
(anti-mouse or anti-human, Becton-Dickinson, Franklin Lakes, NJ, USA) for 40 min. After
three washes the cells were resuspended in 300 μl of PBS and evaluated by flow cytometry (Fax-
Calibur, Becton-Dickinson).
NMR spectroscopy
The NMR spectra of the synthetic peptide (DFEDVWNSSYG) were obtained for 2H2O solu-
tions at 25°C with a Bruker AVANCE III 600 MHz spectrometer (Bremen, Germany), using
acetone (δH 2.225 and δC 31.05) as the internal reference. The main groups of signals were as-
signed by one- and two-dimensional experiments (COSY, TOCSY, ROESY, HMBC, and
HSQC-DEPT). In the TOCSY experiments the mixing times were 30, 60, and 100 ms. The
delay in the HMBC experiments and the mixing time in the ROESY experiments were 60 and
200 ms, respectively. The data were acquired and processed using standard Bruker software.
The processed spectra were assigned with help of the SPARKY program [31].
One-dimensional STD NMR experiments were performed at 25°C with a 5-mm inverse-
detection QCI cryoprobe equipped with z-gradient. Spectra were recorded using the pulse pro-
grams bundled with the Topspin software. The excitation sculpting pulse sequences were used
to suppress water signals in the spectra. The broad resonances of a protein were suppressed
with a 20-ms spin-lock pulse. The protein was irradiated at δH −0.5 ppm and 9.5 ppm (on-
resonance) and δH30 ppm (off-resonance) with a train of Gaussian shaped pulses (50 ms) and
the data were collected as a pseudo2D, split into 1D on-resonance and off-resonance spectra
and followed by calculation of the difference spectra.
Anti-DARCMonoclonal Antibody
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The setup of the STD NMR experiments was optimized in a series of experiments with li-
gand-protein and ligand-only samples to ensure that the irradiation at the selected frequency
did not affect the ligand. The saturation time used in the experiments was 2 s. Samples (total
volume, 160 μl) were prepared in 3 mm NMR tubes, using PBS made with 2H2O, pH 7.5 (not
corrected for 2H2O). Fab/peptide ratios of 1:46 (21 μM Fab with ~1 mM peptide) were used.
Analysis of Peptides Structure and Folding
The secondary structure and folding of DFEDVWNSSYG and peptides with Val-25 substitu-
tions were predicted and calculated by PEP-FOLD, an online resource for de novo peptide
structure prediction in aqueous solutions [32]. The PEP-FOLD provides pdb (Protein Data
Bank) files with representation of different peptide models combined in clusters. The models
obtained by molecular modeling of peptides with the lowest sOPEP energy (sOPEP—
Optimized Potential for Efficient Structure Prediction) were used for further analysis. The pdb
files were visualized and analyzed by Chimera software and the distances between Trp-26, Tyr-
30 and Phe-22, residues involved in the peptide-antibody interaction were calculated [33].
Results
Evaluation of the epitope recognized by 2C3 monoclonal antibody
Soluble ECD1-nuc constructs with consensus-type sequence or the sequence containing amino
acid substitutions were tested by ELISA for ability to inhibit binding of the antibody to ECD1-
nuc immobilized on a polystyrene plate. Profiles of inhibition of 2C3 MAb by different ECD1-
nuc constructs are shown in S3 Fig. The binding strength of a given construct to antibody was
calculated as the concentration of protein required for 50% inhibition of binding to the immo-
bilized wild type construct (Table 1). The results demonstrate that only constructs in which
Trp-26 is present in the epitope can inhibit, at low concentration, binding of the 2C3 antibody
to coated ECD1-Nuc (Table 1, compare rows 1-3 with rows 4-8). Substitution of this residue
by another aromatic amino acid or Ala results in a decrease of inhibition (Table 1, rows 6-8).
However, this effect was somewhat compensated for when a negative charge was introduced at
position 30 by replacing Tyr with Glu (Table 1, rows 4 and 5).
The influence of Tyr-30 sulfation was tested using sulfated and non-sulfated synthetic pep-
tides encompassing amino acid residues 21-31 of ECD1 and evaluating ability to inhibit bind-
ing to ECD1-Nuc: results of the inhibition of 2C3 MAb binding to ECD1-Nuc by these
peptides evaluated by ELISA is shown in Fig. 1. The SPR analysis revealed that concentration
Table 1. Inhibition of binding of 2C3 MAb to ECD1-nuc constructs evaluated by ELISA.
No. Sequence Concentration required for 50% inhibition [μg/ml]
1 FEDVWNSSY 0.17±0.19
2 FEDVWNSSE 0.22±0.12
3 FEDVWNSSA 0.3±0.34
4 FEDVFNSSE 28±1.23
5 FEDVANSSE 48±1.45
6 FEDVFNSSA >100
7 FEDVANSSY >100
8 FEDVANSSA >100
Concentrations of soluble ECD1-nuc constructs required for 50% inhibition of antibody binding to coated
wild type ECD1-nuc are shown.
doi:10.1371/journal.pone.0116472.t001
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required for 50% inhibition of 2C3 MAb binding is 410 nM (±40) for DFEDVWNSSYG and
252 nM (± 20) for DFEDVWNSSY(SO3)G. Thus, sulfation of Tyr-30 is associated with a higher
binding ability of the peptide to the antibody. In addition, to further investigate the role of sul-
fation of Tyr-30, we modified this residue in ECD1-nuc immobilized on a Biacore chip. Be-
cause a sulfotransferase is not commercially available, we used Src kinase to introduce a
phosphate to the Tyr-30 residue to mimic a sulfate group. As a control, we used an anti-
phosphotyrosine antibody which bound to ECD1 only after Src kinase treatment (data not
shown). The kinetic data showed that phosphorylation of Tyr-30 caused an increase of 2C3 af-
finity, mainly by increasing ka (Table 2 rows 1 and 4).
This set of experiments was completed with the studies performed using transfected K562
cells expressing wild type or mutated DARC. The binding of 2C3 antibody was evaluated by
flow cytometry, and the strength of binding was estimated as a ratio between the percentages of
cells bound by 2C3 MAb to the percentage of cells bound by anti-Fya antibody (clone 655),
which recognizes the 41YGANLE46 epitope [25]. We found that only the cells transfected with
constructs encoding Trp at position 26 were bound by the antibody with high affinity (Table 3
rows 1-5), whereas substitution of that residue with alanine resulted in a dramatic decrease of
Figure 1. Inhibition of 2C3 MAb binding to ECD1-nuc. The antibody was incubated with serially diluted
DFEDVWNSSYG (circles) or DFEDVWNSSY(SO3H)G (squares) peptides. Subsequent binding to ECD1-
nuc was evaluated by ELISA as described in Materials and Methods. The difference in % of inhibition was
statistically significant in the range of concentrations 3-60 nM (P< 0.05, two-tailed Mann-Whitney U test).
doi:10.1371/journal.pone.0116472.g001
Table 2. Kinetic constants of 2C3 Fab binding to ECD1-nuc and purified DARC measured by SPR.
Ligand ka (M-1s-1) kd(s-1) KD(M)
1 ECD1-nuc 5.39 × 104 7.66 × 10-4 1.42 × 10-8
2 DARC from K562 cells 2.076 × 106 5.472 × 10-4 2.626 × 10-10
3 DARC from K562 cells after deglycosylation 9.754 × 106 2.757 × 10-4 2.826 × 10-11
4 ECD1-nuc after phosphorylation 1.692 × 106 7.769 × 10-4 4.592 × 10-10
doi:10.1371/journal.pone.0116472.t002
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the binding (Table 3, rows 6-8). When Trp-26 was substituted with Phe, the binding was re-
duced five times, but was not completely abolished (Table 3, row 9), suggesting that an aromat-
ic ring at position 26 may to some extent substitute for the indole present in Trp residues. The
flow cytometry experiments also confirmed the role of Tyr-30 and tyrosine sulfation, since sub-
stitution of Tyr-30 by Ala caused a decrease of 2C3 MAb binding (Table 3, row 2), while substi-
tution of Tyr-30 by Glu increased the binding to some extent (Table 3, row 3). These data were
consistent in ELISA and SPR experiments.
To evaluate the influence of glycosylation on 2C3 MAb binding, the recombinant DARC
purified from K562 cells (S1 Fig.) was immobilized on the chip and the oligosaccharides were
removed by PNG-ase F. The Sambucus nigra agglutinin (SNA) lectin which recognizes termi-
nal residues of sialic acids was used to evaluate if the reaction was complete. It was shown be-
fore that terminal sialic acid residues are present in oligosaccharide chains of DARC [20, 21].
We found that binding of SNA was largely decreased after treatment of the immobilized pro-
tein by PNG-ase F (data not shown), while affinity of the antibody increased (Table 2, rows 2
and 3), suggesting that oligosaccharide chains, which are not part of the epitope, may in fact
hinder partially access of the antibody to the peptide backbone.
In contrast, when binding of 2C3 MAb was evaluated using K562 cells transfected with the
vector encoding DARC without glycosylation site at Asn-27, no difference in binding was ob-
served between such construct and consensus DARC (Table 3, compare rows 1 and 4). It may
be argued that the affinity increase observed in the SPR experiment could not be detected when
the less sensitive flow cytometry technique was employed.
Cloning and expression of 2C3 Fab
The 2C3 Fab fragment was cloned and expressed in E. coli and purified (S2 Fig.), and evaluated
by ELISA and surface plasmon resonance (Table 4). The accession numbers for variable re-
gions of the light and heavy chains are KP179400 and KP179401, respectively.
It was found that the affinity of 2C3 Fab is about two times lower (statistically significant at
concentration 20 nM, P< 0.05, two-tailed Mann-Whitney U test) than the affinity of 2C3 par-
ent antibody (Fig. 2).
The lower affinity is an asset to STD-NMR studies as discussed below.
Table 3. Binding of anti-Fya and 2C3 MAb to DARC mutants expressed in K562 cells measured by
flow cytometry.
SEQUENCE % pos 2C3 Mab % pos Fya MAb
1 FEDVWNSSY 0.97±0.07
2 FEDVWNSSA 0.75±0.03
3 FEDVWNSSE 1.16±0.09
4 FEDVWNSAY* 0.97±0.04
5 FEDVWNSAA* 0.95±0.03
6 FEDVANSSY 0.04±0.01
7 FEDVANSAE* 0.08±0.02
8 FEDVANSAY* 0.00
9 FEDVFNSSY 0.19±0.02
Ratio of percentage of cells recognized by 2C3 antibody to percentage of cells recognized by anti-Fya
antibody obtained for each clone is shown. Cells showing mean fluorescence above 102 were considered
as a positive.
* site N27 is not glycosylated
doi:10.1371/journal.pone.0116472.t003
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STD-NMR studies of interaction between 2C3 Fab and its epitope
The role of structural elements within the peptide that contribute to the Fab-binding epitope
were investigated by STD NMR [34, 35] using synthetic peptide DFEDVWNSSYG. We found
that the enhanced resonances in the STD NMR spectrum belonged predominantly to protons
ε3, z2, z3, η2 and δ1 of the Trp-26 residue (the enhanced resonances are indicated in Fig. 3).
Minor enhancements of the resonances of protons ε1/ε2 and δ1/δ2 of the Phe residue were
also observed. The enhanced resonance at ~7.12 ppm could not be assigned unequivocally as
protons δ1/δ2 of Tyr residue and proton z3 of the Trp were not resolved. Minute enhance-
ments of Tyr protons ε1/ε2 were only noticeable when the on-resonance irradiation frequency
was set to 9.5 ppm. Additionally, no substantial enhancements were observed in the region of
signals from aliphatic side chains. Interestingly, no enhancements of valine (V) CH3 proton
resonance were observed. No enhancement of Val-35 STD signal gives evidence of either the
lack of binding or too strong binding and low off rate value or insufficient energy transfer from
the protein to this residue due to the unfavorable conformation causing the distance too large
for STD signal observation. The STD-NMR experiments confirmed that the immunodominant
Table 4. Kinetic constants of 2C3 MAb and 2C3 Fab binding to ECD1-nuc measured by SPR.
ka kd KD
2C3 Fab 0.998 × 104 9.259 × 104 9.305 × 10-8
2C3 MAb 4.62 × 104 5.11 × 10-5 1.1 × 10-9
doi:10.1371/journal.pone.0116472.t004
Figure 2. Comparison of binding of 2C3 MAb and 2C3 Fab to ECD1-nuc evaluated by ELISA. The
binding of 2C3 MAb (squares) and 2C3 Fab (circles) was evaluated by ELISA as described in Materials and
Methods. The difference in binding is statistically significant at concentration 20 nM (P< 0.05, two-tailed
Mann-Whitney U test).
doi:10.1371/journal.pone.0116472.g002
Anti-DARCMonoclonal Antibody
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epitope recognized by the Fab is limited predominantly to the Trp residue within the peptide.
However, the intensities of the enhanced signals observed in the STD NMR spectrum were
low. This could be explained by the tight binding of the Fab to the peptide and presumably
small off rates (koff) resulting in an inefficient saturation transfer to ligand.
Modeling of the peptide structure
In order to figure out why Val-25, which seemed to be indispensable part of the eptiope, does
not interact directly with the antibody, structures of peptide DFEDVWNSSYG and peptides
with Val-25 substituted with other amino acids were evaluated using PEP-FOLD webserver.
The most relevant peptides conformations, i.e. associated with lowest sOPEP energies, were
Figure 3. STD-NMR analysis of the Fab-binding epitope. The STD NMR (bottom) and reference 1H NMR spectra of the peptide DFEDVWNSSYG
(diagram) in the presence of Fab were acquired at 600 MHz and 25°C for samples (160μl, in a 3 mm tube) prepared in PBSmade with 2H2O, pH 7.5. The
protein was irradiated at δH 9.5 ppm (on-resonance) and δH30 ppm (off-resonance) with a saturation time of 2 s. The excitation sculpting pulse sequence was
used to suppress water signals. The oversized one-letter amino acid codes indicate the proton resonances that were enhanced in the STD experiments. The
Greek letters and numbers designate the enhanced resonances of the aromatic systems. The unresolved resonances are grouped.
doi:10.1371/journal.pone.0116472.g003
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selected for further analysis (S1 Table). Based on a structural alphabet approach [36] and a
coarse-grained protein force field for structure fold prediction [37], PEP-FOLD proposed vari-
ous local peptide structures near to their native conformations. Experimental 3D structure of
the Gln-19—Tyr-30 portion of DARC was extracted from published DARC-PvDBP complex
(PDB 4NUU) [5], it was compared with peptide models obtained in our in silico studies. Struc-
tures of peptide models based on sOPEP energy show striking similarities to the experimental
one. The degree of similarity of experimental and predicted structures was evaluated by com-
puting backbone RMSD (root-mean square deviation): RMSD values range between 0.69 and
0.83 Å. This strongly supports the pertinence of our modeling approach. Moreover the dis-
tances between Trp-26, Tyr-30 and Phe-22 in the peptide DFED[V, I, E, L]WNSSYG, were cal-
culated (S1 Table), and show some significant differences underlining the influence on the
peptide structure of the amino acid present at position 25.
Indeed the peptide models shown in Fig. 4 and S1 Table demonstrate how Val-25 substitu-
tion alter the epitope 3D structure and may influence binding to 2C3 MAb. The distances be-
tween residues involved in binding of the antibody are slightly different for those models. The
substitution of Val (HI = 4.2) with Ile residue, an amino acid with higher hydrophobic index
(HI = 4.5) but longer aliphatic chain does not cause significant structure deformation (0.45 to
0.66 Å more than for Val-25 model, S1 Table). Val-25 substitutions with amino acids such as
Ala (HI = 1.8) and Leu (HI = 3.8) change the epitope conformation and extend the distances
between amino acids involved in the interaction with antibody 2C3. Leu and Ala substitutions
imply 0.09-2.019 and 0.15-2.29 Å shifts compared to Val-25 model, respectively.
Moreover, conformational changes of particular amino acids side-chains, which may impact
the epitope formation, were also observed (Fig. 4).
Discussion
As the role of monoclonal antibodies in biology and medicine becomes increasingly important,
so does the precise evaluation of the epitopes being recognized by the antibodies. There are
Figure 4. Three-dimensional structure of the peptide DFEDVWNSSYG (a) and peptides in which Val-
25 is substituted by amino acids of different hydrophobicity (b-d). Peptide structures were calculated in
PEP-FOLD and then visualized and analyzed in Chimera software. The amino acid residues involved in the
antibody binding are visualized in red, while the residue that was changed: Val (a), Ile (b), Leu (c) and Ala (d)
is visualized in purple.
doi:10.1371/journal.pone.0116472.g004
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many methods allowing to precisely define amino acid residues that are involved in antibody
binding, such as evaluation of binding of the antibody to synthetic peptides (Pepscan analysis)
or to recombinant peptides expressed either in bacteria on in eukaryotic cells [26, 38–43]. Re-
cently, saturation transfer difference spectroscopy NMR (STD-NMR) has been increasingly
used in epitope-antibody studies, although majority of antibodies evaluated by this method
bind carbohydrate antigens [44–46]. In this paper we used a variety of methods, including
STD-NMR, to precisely define the peptidic epitope of 2C3 MAb.
The murine monoclonal antibody 2C3 is one of the widely used anti-DARC antibodies.
Since its binding interferes with some of the DARC functions such as chemokine binding [24],
and invasion of erythrocytes by P. vivaxmerozoites [27], precise knowledge on the recognized
epitope seems necessary for its potential applications.
Our results unequivocally re-establish the important role of Trp-26 in DARC recognition
by the antibody confirming the data published by Wasniowska [24], as it cannot be replaced by
any residue without significant decrease of affinity. However, when Trp-26 is substituted by
Phe, binding of 2C3 MAb was not abolished completely, suggesting that the aromatic ring may
substitute the indole ring. The role of Tyr-30 has also been clarified: it can be substituted with
Ala without strongly decreasing the affinity, which stands in contrast with the results published
previously [25]. However, our results suggest that sulfation of Tyr-30 causes an increase of the
antibody affinity to some extent. Moreover, when ECD1-nuc construct contained both Phe at
position 26 and Glu at position 30, the binding of the antibody increased in comparison to the
construct with Phe-26 only. Finally, phosphorylation of Tyr-30 on ECD1-nuc used to mimic
sulfation, caused and increase of the 2C3 MAb affinity. These data suggest that the negative
charge at Tyr-30 possibly increases the antibody—antigen interaction.
Results of STD-NMR presented in this paper support these conlusions. Saturation transfer
difference (STD)-NMR technique can be used to identify the proton resonances of a ligand in
close contact with the binding protein: side chains within the ligand that interact most strongly
show a strong STD effect. There are several reports in which interaction between receptor and
peptide ligand [47, 48] or monoclonal antibody and oligosaccharide epitope [44, 49, 50] is eval-
uated. However, only a handful of papers exist in which interactions between monoclonal anti-
body and peptide epitope are studied [45, 51]. The main limitation of the technique is the
dissociation constant, which must be in range 10-3 to 10-8M [34, 35]. In the case of 2C3 anti-
body, the KD is too low (1.1 × 10
-9M) so we decided to use Fab fragment, whose KD is 9.3 ×
10-8M. Evaluation of interaction of peptide DFEDVWNSSYG with 2C3 Fab by STD-NMR
technique confirmed that Trp-26 plays a major role in the antibody binding. It was found that
interaction between Phe-22 and the antibody is weaker, whereas Tyr-30 shows the weakest in-
teraction. Thus, only aromatic residues have been identified by STD-NMR, while other resi-
dues (such as Val-25) cannot be resolved in the spectrum. The Val-25 seems to play an
important role in the epitope, because it was shown before that it cannot be replaced by another
residue (with exception of Ile) without losing ability to bind 2C3 antibody [24].
In order to explain the possible role of Val-25 in the epitope, we used in silicomodeling of
DFEDVWNSSYG peptide, and of peptides with Val-25 substituted by Ile, Leu or Ala. Our
models suggest that Val-25 substitution by Leu or Ala implies changes in peptide conformation
and moves slightly the hydrophobic amino acids away from each other. However, it must be
noted that the Ile side chain (which is longer than Val) might have an influence on epitope for-
mation. The modeling suggests that Val-25 might cramp with other hydrophobic amino acids
and control the polypeptide structure. Thus, substitution of Val-25 with other amino acid resi-
dues with different hydrophobicity may alter this structure by rendering Tyr-30 further from
the epitope (S4B Fig.). Modeling studies showed that the essential residues forming the epitope
(Phe-22, Trp-26 and Tyr-30) are exposed one face of the helix while Val-25 located on the
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opposite face of the helix might not participate to contacts with antibody. We hypothesize
though that Ile, which has a longer side chain than Val, might in some way make some steric
hindrance to the antibody epitope interaction since modeling suggests that it does not modify
grossly epitope structure. In summary, the peptide structure of the epitope seems to be com-
pact, with aromatic residues forming a single block on one side of an helix (Fig. 4).
Taken together, our results confirm that the minimal DARC epitope recognized by 2C3
MAb is linear and consists of five amino acids: 22FEDVW26, but there is a certain interaction
between Tyr-30 and the antibody as shown by STD-NMR. In addition, we found that when
Tyr-30 was substituted by a residue with a negative charge, such as glutamic acid, binding of
2C3 antibody was slightly increased despite other crucial amino acid substitutions, suggesting
that the negative charge at amino acid 30 may play an auxiliary role in recognition. In vivo, the
negative charge is provided by the Tyr-30 due to its sulfation.
Our results were obtained using a set of methods that are applicable for establishing epitope
of any monoclonal antibody. We have demonstrated that using eukaryotic and prokaryotic ex-
pressed constructs, any doubts regarding antibody specificity can be clarified. We also showed
usefulness of SPR analysis to demonstrate influence of post-translational modifications by car-
rying out enzymatic reactions “in situ” on the protein previously immobilized on the chip. In
addition, we showed that STD-NMR technique can be used to evaluate binding of an antibody
to a peptide, which to our knowledge is one of the first experiments of this kind described
in literature.
Supporting Information
S1 Fig. Analysis of immunoaffinity chromatography on immobilized anti DARC VHH.
Lanes 1: molecular weight standard (molecular weight of bands is noted on the left), supple-
mented with purifed anti DARC nanobody. Lane 2 and 4 20 μl of fractions collected during
wash of the column with Tris saline 0.3% C12E8 buffer. Lane 3 and 5: 20 μl of material eluted
from the coulmn with DFEDVW peptide. Lane 6 contains 20 μl of material eluted from column
with 0.1 M glycine buffer. Lanes 1-3: silver nitrate staining, lanes 4-5: Western blotting with
2C3 MAb.
(TIF)
S2 Fig. SDS-PAGE analysis of purified soluble 2C3 Fab. Lane 1: molecular weight standards.
The purified protein (4 μg) were loaded onto 10% polyacrylamide gel in the absence (A) or
presence (B) of 2-mercaptoethanol, and visualized with Coomasie Brilliant Blue.
(TIF)
S3 Fig. Inhibion of binding of 2C3 MAb to ECD1-nuc constructs evaluated by ELISA. 2C3
MAb was incubated with ECD1-nuc constructs in different concentration as described in Ma-
terials and Methods, and subsequent binding to ECD1-nuc—covered plates was evaluated by
ELISA.
(TIF)
S4 Fig. The 3-D structure of DARC bound to PvDBP (PDB 4NUU) as visualized by Chime-
ra software (A) and compared to peptide models obtained in in silico studies (B). DBP-RII
molecules are shown in blue and green, DARC molecule is shown in red [5]. DARC was en-
larged on the right and the crucial residues were highlighted using different colors: Phe-22
(purple), Val-25 (red), Trp-26 (green), Tyr-30 (blue). Q19-Y30 peptide from DARC (red) was
enlarged and compared to peptide models (black) obtained in in silico studies: (a)
DFEDVWNSSYG (RMSD = 0,75), (b) DFEDIWNSSYG (RMSD = 0,83), (c) DFEDLWNSSYG
(RMSD = 0,70), and (d) DFEDAWNSSYG (RMSD = 0,67); B. 3-D structure of peptides
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obtained in modelling studies. Amino acids exposed on the same face of the helix, involved in
antibody binding, are shown in purple (Phe-22), green (Trp-26) and blue (Tyr-30). Residues
located on the other surface of the helix (Val-25, Ile-25, Leu-25 and Ala-25) are shown in red.
(TIF)
S1 Table. The representative structure models of the native DFEDVWNSSYG peptide and
peptides with Val-25 substitution. Three-dimensional structure of sOPEP energy model was
calculated by PEP-FOLD server. The distances between Trp-26, Tyr-30 and Phe-22 were calcu-
lated by Chimera software. The colors show hydrophobicity of surface amino acids in the
Kyte-Doolittle scale (blue for the most hydrophilic to white at 0.0 and to orange red for the
most hydrophobic). Peptide models underline the influence of hydrophobic/hydrophilic
amino acids on position 25 (Val, Ile, Leu, Ala) on peptide folding.
(DOCX)
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